OrbiMed Capital GP VI LLC
CIK 1682115 · last filed 2025-08-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$793.80M
Companies
19
Total Filings
42
Lifetime Open-Market Net
-$105.94M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Turnstone Biologics Corp. (TSBX) Delisted | Director | 0 | $0.35 | $0 | $0 | 1 | 2025-08-12 |
| NPCE | 10%+ Owner | 3,272,199 | $15.31 | $50.10M | $2.51M | 4 | 2025-05-16 |
| CMPX | Director | 15,219,994 | $2.04 | $31.05M | -$17.04M | 1 | 2025-04-11 |
| IRON | Director | 776,844 | $74.65 | $57.99M | -$67.86M | 1 | 2025-03-12 |
| SPRY | Director | 8,019,187 | $5.67 | $45.47M | -$25.19M | 2 | 2024-08-23 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 0 | $64.97 | $0 | $4.00M | 2 | 2024-05-20 |
| EWTX | Director | 14,436,497 | $40.35 | $582.51M | $47.25M | 3 | 2024-01-25 |
| ImageneBio, Inc. (IKNA) Delisted | Director | 13,107 | $17.16 | $224.9K | $0 | 1 | 2023-09-21 |
| Verona Pharma plc (VRNA) Delisted | Director | 4,180,691 | $106.91 | $446.96M | -$19.88M | 1 | 2023-05-15 |
| scPharmaceuticals Inc. (SCPH) Delisted | 10%+ Owner | 5,328,328 | $5.67 | $30.21M | $47.01M | 2 | 2022-11-29 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | 10%+ Owner | 5,629,842 | $46.99 | $264.55M | -$242.57M | 8 | 2022-09-14 |
| ORIC | Director | 2,240,440 | $11.91 | $26.68M | -$1.28M | 4 | 2021-03-31 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | 507,423 | $5.87 | $2.98M | $75.00M | 1 | 2020-12-08 |
| 89bio, Inc. (ETNB) Delisted | Director | 2,002,221 | $14.84 | $29.71M | $53.60M | 1 | 2019-11-13 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | 10%+ Owner | 317,921 | $33.99 | $10.81M | $9.00M | 1 | 2018-07-24 |
| KALA | 10%+ Owner | 1,381 | $0.66 | $912 | $13.52M | 4 | 2018-02-12 |
| Adicet Bio, Inc. (TORC) Delisted | Director | 346,498 | — | — | $16.00M | 1 | 2018-01-30 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 135,333 | $0.69 | $93.4K | $0 | 1 | 2018-01-30 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 5,000,000 | $9.09 | $45.45M | $0 | 1 | 2017-06-15 |
Recent Filings · Page 3 of 5
42 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-23 | NPCE | Buy (P) | +470,000 | $7.99M | EDGAR |
| 2021-03-31 | EWTX | Mixed | +40,086,405 | $17.25M | EDGAR |
| 2021-03-31 | ORIC | Sell (S) | −206,848 | -$4.86M | EDGAR |
| 2021-03-23 | ORIC | Sell (S) | −65,880 | -$1.73M | EDGAR |
| 2021-03-18 | ORIC | Sell (S) | −132,404 | -$3.70M | EDGAR |
| 2021-03-03 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −2,440,000 | -$202.98M | EDGAR |
| 2021-01-26 | — | U | −27,644,926 | $0 | |
| 2020-12-08 | ARS Pharmaceuticals, Inc. (SBTX) Delisted | Mixed | +24,606,726 | $75.00M | EDGAR |
| 2020-04-28 | ORIC | Mixed | +5,531,434 | $9.00M | EDGAR |
| 2019-11-13 | 89bio, Inc. (ETNB) Delisted | Mixed | +13,572,864 | $53.60M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.